Myeloproliferative Neoplasms Clinical Trial

Clinical Trial Finder Myeloproliferative Neoplasms Trials

Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia

See Locations Near You

Summary

The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with leukemia-cml/" >CML

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Ph+ CML on dasatinib therapy
Loss of cytogenetic or molecular response while on dasatinib therapy
On stable dose of dasatinib for a minimum of 12 weeks and with < 14 day interruption of treatment

Exclusion Criteria:

Blast crisis CML
Autoimmune disease
Uncontrolled or significant cardiovascular disease

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 1

Study ID:

NCT00732186

Recruitment Status:

Withdrawn

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

The University Of Texas, M.D. Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 1

Study ID:

NCT00732186

Recruitment Status:

Withdrawn

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider